Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

Table 3 Univariate and multivariate analyses for re-relapse after complete remission

Characteristics	Relapse
Univariate analysis	P
Age	0.468
Gender	0.521
Diagnosis	0.211
Remission status pre-HSCT	0.748
Cytogenetic subgroups^a	0.294
Numbers of induction chemotherapies	0.654
Donor types	0.735
HLA-mismatch	0.090
Donor-patient sex match	0.932
ABO match	0.154
Conditioning regimen	1.000
Acute GvHD of grades 2–4 pre-DLI	0.726
Chronic GvHD pre-DLI	0.703
Interval from HSCT to relapse	0.695
BM blasts at the time of relapse	0.443
Chimerism at the time of relapse	0.467
MNCs in DLI	0.388
CD3⁺ cells in DLI	0.252
CD4⁺ cells in DLI	0.242
CD8⁺ cells in DLI	0.348
CD14⁺ cells in DLI	0.209
CD34⁺ cells in DLI	0.817
Acute GvHD of grades 2–4 post-DLI	0.413
Chronic GvHD post-DLI	0.002
Persistent MRD-positive state post-DLI	0.001
Multivariate analysis	P	HR
Persistent MRD-positive state post-DLI	<0.0001	21.04
No chronic GvHD post-DLI	0.035	3.56

HSCT hematopoietic stem cell transplantation, HLA human leucocyte antigen, GvHD graft-vs.-host disease, DLI donor lymphocyte infusion, BM bone marrow, MNC mononuclear cell, MRD minimal residual disease
^aThe cytogenetic subgroups are according to the published data [35, 36]

ISSN: 1756-8722